1. Home
  2. MDXH vs BSEM Comparison

MDXH vs BSEM Comparison

Compare MDXH & BSEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.57

Market Cap

68.7M

Sector

N/A

ML Signal

HOLD

Logo BioStem Technologies Inc. Common Stock

BSEM

BioStem Technologies Inc. Common Stock

N/A

Current Price

$4.03

Market Cap

76.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MDXH
BSEM
Founded
2003
N/A
Country
Belgium
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
76.9M
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
MDXH
BSEM
Price
$0.57
$4.03
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $7.67
N/A
AVG Volume (30 Days)
★ 206.0K
142.9K
Earning Date
05-14-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$30.78
N/A
Revenue Next Year
$18.31
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$2.25
52 Week High
$5.33
$5.44

Technical Indicators

Market Signals
Indicator
MDXH
BSEM
Relative Strength Index (RSI) 36.37 51.58
Support Level $0.51 $3.66
Resistance Level $0.75 $4.65
Average True Range (ATR) 0.04 0.49
MACD -0.02 -0.02
Stochastic Oscillator 2.53 22.62

Price Performance

Historical Comparison
MDXH
BSEM

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About BSEM BioStem Technologies Inc. Common Stock

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.

Share on Social Networks: